Article Sidebar
Published:
Jan 26, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Delicaflavone induces apoptosis and autophagy, and improves the cytotoxicity of multiple myeloma cells to cisplatin by inactivating the AKT/mTOR pathway
Abstract
Purpose: To determine the effects of delicaflavone in multiple myeloma cells.
Methods: Multiple myeloma cells were incubated with different concentrations of delicaflavone (20, 40, and 80 μM) or coincubated with 40 μM delicaflavone and 20 μM cisplatin. Cell viability and proliferation were investigated using MTT and colony formation assays, respectively. Flow cytometry and western blot analysis were applied to investigate cell apoptosis and autophagy.
Results: Treatment with delicaflavone decreased cell viability and proliferation of multiple myeloma cells but promoted cell apoptosis in a dose-dependent manner. Protein expression of Autophagy-related protein 7 (Atg7) and LC3-II/LC3-I were increased by delicaflavone treatment, while p62 was decreased by the same treatment. Delicaflavone also conferred cisplatin sensitivity in multiple myeloma cells through decreases in cell viability and in cell proliferation. AKT/mTOR phosphorylation was reduced in multiple myeloma cells treated with delicaflavone.
Conclusion: Delicaflavone induces apoptosis and autophagy of multiple myeloma cells, and confers cisplatin sensitivity through inactivation of the AKT/mTOR pathway.
